The Journey Towards Lung Protective Respiratory Support in Preterm Neonates

Thomas M. Berger Matteo Fontana Martin Stocker
Neonatal and Pediatric Intensive Care Unit, Children’s Hospital of Lucerne, Lucerne, Switzerland

Key Words
Antenatal corticosteroids · Atelectrauma · Bronchopulmonary dysplasia · Continuous positive airway pressure · Conventional mechanical ventilation · High-frequency oscillatory ventilation · Lung-protective strategies · Noninvasive respiratory support · Oxygen toxicity · Surfactant · Volutrauma

Abstract
The aim of this conceptual review is to provide the reader with a broad perspective on progress made in respiratory support of preterm infants over the past five decades. Landmark discoveries are described in their historical context and underlying theories of lung protection are discussed. The review finishes by integrating different approaches and perspectives into a state-of-the-art concept for lung-protective ventilation in this fragile patient population. Improvements in neonatal respiratory support in the 1970s and 1980s have contributed to dramatic improvements of mortality and morbidity rates among neonates with respiratory failure. Continuous positive airway pressure, antenatal corticosteroids and surfactant replacement therapy revolutionized the care of preterm infants. With the recognition that atelectrauma, volutrauma and oxygen toxicity are the main factors contributing to ventilator-induced lung injury, lung-protective strategies, including noninvasive respiratory support, tidal volume targeting during conventional mechanical ventilation and high frequency ventilation were developed in the 1990s. Given the fact that progress made in the last decade has only resulted in minor improvements in mortality and morbidity rates of neonates with respiratory failure, it seems unlikely that further refinements of current technologies will produce giant leaps forward in high-resource countries. It appears that entirely new approaches would be required. In contrast, knowledge and technology transfer of basic respiratory support strategies (e.g. use of oxygen, simple systems to provide continuous positive airway pressure), could have an enormous impact on the prognosis of neonates with respiratory failure in low-resource countries.

Introduction
Progress made in the field of perinatology over the past five decades has led to dramatically improved mortality and morbidity rates among sick newborn infants. While advances in prenatal care and regionalization of perinatal care have played an important role, the most important changes that have contributed to this success have occurred in the field of neonatal respiratory care.

This review will describe the journey towards lung protective respiratory support in neonates. Progress made over the past five decades has been outstanding. The vast majority of infants with respiratory failure who were doomed in the 1960s can now be expected to survive.
Before 1960: Missteps, Falls and a First Important Milestone

Sixty years ago, for newborn infants with respiratory distress of various etiologies, the provision of supplemental oxygen was the sole therapeutic option and its impact could only be assessed clinically. When it was recognized that exposure to high concentrations of oxygen could cause retrolental fibroplasia (now known as retinopathy of prematurity or ROP) and result in blindness [1], a strategy of restricted oxygen use was adopted but may have resulted in increased mortality rates from respiratory failure.

In 1959, Avery and Mead [3] published their seminal observation of an increased surface tension in lung liquid samples from babies who had died from hyaline membrane disease (HMD) and suggested that preterm infants lacked a surface-active agent (i.e. surfactant). In those days, preterm infants who developed HMD either died within the first 3 days of life or recovered completely after 7–10 days [4]. It would take another 20 years until the first report of surfactant replacement therapy would be published [5]; in the meantime, a series of discoveries started to change the hitherto dire prognosis of neonates with respiratory failure.

The 1960s: Marching into the Bronchopulmonary Dysplasia Epidemic

1963 was a pivotal year for the new field of neonatology, when the son of President John F. Kennedy, Patrick Bouvier Kennedy, died from complications of HMD on his third day of life after having been born at 34 weeks’ gestation with a birth weight of 2,100 g. At that time, the first experiences with invasive mechanical ventilatory support of neonates outside of the delivery room and beyond the immediate postpartum period had already been published. The death of the son of the American President accelerated the development and deployment of infant ventilators, micro-blood gas analysis and umbilical artery catheterization, and led to the development of intensive care for newborns in the 1960s on both sides of the Atlantic.

In those early years of neonatal mechanical ventilation, air leak syndromes and its complications were very common and felt to be related to high airway pressures (i.e. barotrauma). Nevertheless, the addition of mechanical ventilation to the neonatal intensive care unit (NICU) armamentarium improved survival rates of neonates with respiratory failure. However, in contrast to the natural history of HMD observed 10 years earlier [4], complete recovery was no longer the only outcome in survivors as many went on to develop a new form of chronic lung disease. Based on its histological features, the term bronchopulmonary dysplasia (BPD) was introduced by Northway et al. [6] who published their observations in 1967. Infants who required high concentrations of supplemental oxygen and high peak inflation pressures were at greatest risk to develop BPD [6].

The 1970s: Giant Leaps Forward

Two discoveries made in the 1970s, once adopted, had a profound impact on the prognosis of preterm infants. The first one, reported in 1971, was made by Gregory et al. [7] when they were able to demonstrate that continuous positive airway pressure (CPAP) delivered via endotracheal tube or by a sealed head chamber (the ‘Gregory Box’) in preterm infants with HMD dramatically reduced the mortality rate of these infants from an expected rate of 75–20%.

The second discovery was based on the observation that fetal lung maturation could be accelerated by the administration of antenatal corticosteroids (ANC) [8]. In 1972, Liggins and Howie [9] published the results of a randomized controlled trial of ANC, which showed that the risk of HMD and death were both almost halved in ANC exposed preterm infants. These findings were later confirmed by several additional studies and meta-analyses [10].

Perhaps not unexpectedly, with sicker infants surviving, the incidence of BPD was not lowered. In fact, BPD became a veritable scourge of neonatal intensive care. Some affected infants could never be weaned from mechanical ventilation, and, upon graduation from the NICU, were transferred to pediatric intensive care units only to succumb after months to lower respiratory tract infections or chronic right heart failure.

The 1980s: Another Huge Jump

In the 1980s, following the initial observation of a beneficial effect of exogenous surfactant on pulmonary gas exchange in a small case series by Fujiwara et al. [5], several large randomized controlled surfactant trials explored the efficacy of various treatment (prevention versus rescue) and dosing regimens [11]. By the end of the decade, the use of surfactant to prevent or treat HMD was well established and revolutionized the care of these infants who lacked a surface-active agent.
fants. Some years later, when studies clarified the important functions of surfactant-associated proteins, most NICUs switched from protein-free artificial surfactant preparations to the more efficient animal-derived natural surfactants, which contained the hydrophobic surfactant associated proteins SP-B and SP-C [12].

Changing Appearance of BPD

By the end of the 1980s, significant advances had been made in the treatment of premature infants with HMD. Comparing mortality and BPD rates at the Stanford University Medical Center between 1962–1965 and 1989 [13]. Northway [13] was able to demonstrate the dramatic impact the implementation of new techniques in neonatal respiratory care had made over the previous 25 years. With improved survival of more immature infants, the overall incidence of BPD had not changed, but the disease burden had clearly shifted to surviving extremely low birth weight infants (table 1) [13].

The 1990s: Further Steps in the Right Direction

Progress in Conventional Mechanical Ventilation

Parallel to the discoveries of corticosteroid-induced acceleration of fetal lung maturation, CPAP and surfactant replacement therapy, mechanical ventilators were continuously adapted to meet the special needs of neonatal patients. For almost three decades, continuous-flow, time-cycled, pressure-limited devices had been the standard for invasive neonatal ventilatory support. In the 1990s, with the incorporation of microprocessor technology and lightweight flow and pressure transducers, mechanical ventilators became increasingly sophisticated. Clinicians could now choose from a large menu of ventilation modes and modalities [14].

Using flow or pressure sensors and microprocessor technology with short response times, new modes of ventilation were able to synchronize the delivery of mechanical inflations with the patient’s own spontaneous breathing effort. Although the use of patient-triggered modes of mechanical ventilation improved patient-ventilator asynchrony and was associated with a shorter duration of ventilation, other advantages in important clinical outcomes could not be demonstrated [15].

Volume-Targeted Ventilation

By the end of the decade, following an encouraging preliminary report by Amato et al. [16], a large randomized controlled trial confirmed that a lung-protective strategy including positive end-expiratory pressure (PEEP) optimization and tidal volume limitation (6 vs. 12 ml/kg) could decrease mortality rates in adult ARDS patients [17]. Although no comparable studies have been performed in preterm neonates, several clinical trials have shown that volume-targeted ventilation (VTV) delivers more stable tidal volumes than pressure-limited ventilation. In addition, VTV has the advantage of automatically reducing inflation pressures when lung compliance improves with resolution of the underlying pulmonary condition, a process that has been referred to as auto-weaning. A recent meta-analysis of nine randomized trials concluded that VTV significantly reduced the combined rates of death or BPD (RR 0.73, 95% CI 0.57–0.93) with a number needed to treat of 8, whereas there was only a borderline reduction in BPD alone (RR 0.73, 95% CI 0.53–1) [18]. In addition, there were significant reductions in the incidence of pneumothorax, the duration of mechanical ventilation, the incidence of hypocarbia, and the combined outcome of severe intraventricular hemorrhage or periventricular leukomalacia [18]. While these results are encouraging, some caution seems justified as the analysis is based on relatively small trials using a variety of ventilators with different modes of VTV [18, 19]. Currently, no data on long-term neurodevelopmental and respiratory outcomes are available [18].

<table>
<thead>
<tr>
<th>Table 1. Changes in survival and BPD rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival rate</td>
</tr>
<tr>
<td>&lt;1,000 g</td>
</tr>
<tr>
<td>(0/3)</td>
</tr>
<tr>
<td>1,001–1,500 g</td>
</tr>
<tr>
<td>(2/7)</td>
</tr>
<tr>
<td>&gt;1,500 g</td>
</tr>
<tr>
<td>All ventilated infants with RDS</td>
</tr>
<tr>
<td>(13/32)</td>
</tr>
</tbody>
</table>

Improved outcomes of mechanically ventilated infants with RDS at Stanford University Medical Center between 1962–1965 and 1989 [13].

Inclusion criteria: infants ventilated with positive pressure ventilation for HMD for more than 24 h.

Definition of BPD: requirement for supplemental oxygen at 28 days of life.
Introduction of High-Frequency Ventilation into Clinical Practice

Once it had been accepted that atelectrauma, volutrauma and oxygen toxicity were important mechanisms propagating ventilator-induced lung injury, research focused on modes of ventilation that would help stabilize functional residual capacity to prevent collapse of lung units, limit tidal volume to avoid overdistension and minimize oxidative stress. Compared with conventional mechanical ventilation (CMV), high-frequency ventilation appeared more promising to address these issues separately, and animal studies clearly indicated its superiority [20]. Several devices were developed for clinical use, including the most commonly used high-frequency oscillatory ventilators (HFOV), and the less popular high-frequency flow interrupters and high-frequency jet ventilators.

In an important animal study, Carney et al. [21] have shown by in vivo microscopy that in normal lungs alveolar diameters change minimally during tidal ventilation (Ia, b), in injured lungs, there is alveolar collapse at end-expiration during CMV (IIa, b), whereas HFOV is able to maintain alveolar stability (IIc, d). Reproduced with permission from Carney et al. [21].

In 1989, the HIFI Study Group published the results of the first randomized clinical trial comparing efficacy and safety of HFOV and CMV in the treatment of respiratory failure in preterm infants [22]. HFOV did not reduce mortality (18 vs. 17% with CMV; p = 0.73) and had no impact on the incidence of BPD (40 vs. 41% with CMV, p = 0.79).

Meta-analyses of a series of additional trials conducted over the next 20 years showed no evidence of a reduction in mortality at 28 days and only a small reduction in the rate of BPD with the use of HFOV compared to CMV, regardless of whether HFOV was used as a rescue intervention after failed conventional ventilation in near term or term infants (BPD defined as supplemental oxygen at 28–30 days or at discharge home: RR 2.26, 95% CI 0.86–5.90) [23], or electively for the prevention of moderate or severe BPD in preterm infants (RR 0.95, 95% CI 0.88–1.03) [24, 25]. HFOV can be a valuable alternative to conventional mechanical ventilation. Understanding its mechanisms of action and an appreciation of its inherent risks are prerequisites for its successful use [26].

On the Way, BPD Continued to Evolve

Although progress in neonatal respiratory care had continued during the 1990s with the introduction of technologically sophisticated ventilators, its impact on outcome was less impressive compared with the discoveries...
made in the previous decades. Nevertheless, by the end of
the second millennium, gentler ventilation techniques,
ANC and surfactant replacement therapy had minimized
severe lung injury in larger and more mature infants and
BPD had become infrequent in preterm infants with a birth
weight of more than 1,200 g or with a gestational age ex-
ceeding 30 weeks. The disease was now mostly seen in ex-
tremely low birth weight infants and its clinical and radi-
ological appearance had changed significantly (fig. 2) [27].

Apart from alveolar septal fibrosis, which was less pro-
nounced in surfactant-treated infants, the pathology of
the disease in infants born at less than 28 weeks of gesta-
tion was now characterized by a partial arrest in acinar
development [28]. To account for these changes, Jobe
[29] coined the term ‘new BPD’.

The 2000s: Old Roads Revisited

Is a Noninvasive Approach the Way to Go?

Already in 1987, Avery et al. [30] had published a sem-
inual observational study among eight NICUs on center-
specific rates of oxygen dependency at 28 days of life.
They had noted that the center with the least invasive ap-
proach had by far the lowest rate of BPD. This center,
Columbia Presbyterian Medical Center, New York, had
adopted a policy of nasal CPAP as the primary mode of
respiratory support in preterm infants with respiratory
distress, whereas most of the other centers preferred in-
tubation and mechanical ventilation.

During the first decade of the new century, three large
international multi-centre trials were conducted to define
the role of early CPAP [31–33]. Despite slightly different
entry criteria, indications for intubation and surfactant
administration, the results of these trials were remarkably
similar. No trial demonstrated a significant difference in
the primary endpoint (i.e. BPD or death). However, a re-
cent Cochrane review concluded that initial stabilization
with CPAP and surfactant rescue therapy in infants fail-
ing CPAP is associated with less risk of the combined out-
come of BPD or death (RR 1.12, 95% CI 1.02–1.24) com-
pared to elective intubation and prophylactic surfactant
administration [34]. It is noteworthy that the failure rate
of early CPAP is quite high (46–83%) [31–33], and de-
layed intubation, appears to be associated with an in-
creased risk of air leaks [33].

Redefining the Role of Adjuvant Therapies
Surfactant Administration

In 1994, Verder et al. [35] published their experience
with a new strategy that involved intubation, surfactant
administration and rapid extubation to CPAP (later
named the INSURE procedure). In this small-scale study,
surfactant treatment significantly reduced the need for
subsequent mechanical ventilation (43% in surfactant-
treated infants, as compared with 85% in controls, p =
0.003). Several additional trials using INSURE followed
[31, 36–39]. While some of these studies demonstrated a
significantly decreased need for mechanical ventilation
after INSURE [37, 38], this apparent benefit did not trans-
late into decreased rates of mortality or BPD [40]. Finally,
when INSURE is used, prophylactic surfactant is not su-
prior to CPAP and early selective surfactant with regards
to the requirement for mechanical ventilation in the first
5 days of life [41].

In the era of noninvasive respiratory support, neo-
tologists became interested in new techniques of mini-
mally invasive surfactant therapy (MIST). Small feasibil-
ity studies using pharyngeal bolus instillation [42], surfactant administration through a laryngeal mask airway [43], or through a catheter inserted through the vocal cords [44, 45], demonstrated a beneficial effect on oxygenation. Recently, the results of the first multicenter open-label, randomized controlled trial comparing MIST with conventional therapy (i.e. CPAP, rescue intubation and surfactant treatment if needed) in 220 preterm infants with a gestational age between 26 0/7 and 28 6/7 weeks have been published [46]. Although the study showed that the risk for need of any mechanical ventilation was significantly lower after MIST (33 and 73% in the intervention and conventional therapy groups, respectively; \( p < 0.0001 \)), the risk of death or BPD at 36 weeks’ postmenstrual age did not differ (14 and 15%, respectively) [46]. Another recently published single-center study compared INSURE to a modified MIST procedure (the so-called Take Care procedure) which entailed early administration of surfactant via a thin catheter during spontaneous breathing without disruption of CPAP support. In addition to a significantly reduced requirement for mechanical ventilation in the first 72 h of life (30 vs. 45%, \( p = 0.02 \)), the rate of moderate-to-severe BPD in survivors was significantly lower in the Take Care group (10.3 vs. 20.2%, \( p = 0.009 \)) [47].

Inhaled Nitric Oxide

When nitric oxide was identified as the previously propagated endothelium-derived relaxing factor, inhaled nitric oxide (iNO) was felt to be a potentially valuable new therapeutic modality to selectively influence pulmonary vascular tone in sick neonates, and its precise role was subsequently investigated in numerous randomized controlled trials. Initially, infants born at or near term with PPHN were studied. Because infants with PPHN have a high risk of dying, extracorporeal membrane oxygenation was introduced in the 1990s as rescue intervention if conventional therapy failed. A meta-analysis published in 2006 included 14 randomized controlled trials and demonstrated that iNO-treated near-term and term infants were significantly less likely to require extracorporeal membrane oxygenation [48].

When it was shown in preclinical trials that iNO was able to modulate key steps in the pathogenesis of BPD (i.e. decrease lung inflammation and neutrophil infiltration, reverse the inhibition of vascular endothelial growth factor, stimulate angiogenesis and alveolarization) [49], iNO was studied in preterm infants at high risk of developing BPD [50]. Despite these promises, the results of two recently published meta-analyses of studies of iNO in preterm infants were disillusioning: in preterm infants, iNO is neither effective as a rescue therapy for severe respiratory failure, nor in decreasing the incidence of BPD [50, 51].

Caffeine

Methylxanthines such as theophylline and caffeine are frequently used to reduce the frequency of apnea of prematurity and the need for mechanical ventilation. In 2006, the results of the CAP (caffeine for apnea of prematurity) trial showed that caffeine treated infants could be weaned from positive pressure support 1 week earlier (at median postmenstrual ages of 31 and 32 weeks, respectively) and had a lower incidence of BPD (OR 0.63, 95% CI, 0.52–0.76; \( p < 0.001 \)) [52]. Caffeine therapy was also associated with improved neurodevelopmental outcome in survivors at 18–21 months [53], but not at 5 years [54].

The Present: Where Do We Stand Now?

State-of-the Art of Lung-Protective Respiratory Support in Preterm Infants

The major goals of any lung-protective strategy are (1) to avoid atelectrauma by promoting alveolar stability, (2) to limit tidal volume to prevent alveolar overdistension, and (3) to minimize oxygen toxicity by improving V/Q matching. Available data suggest that these goals can be successfully approached by different modes of respiratory support.

It is important to realize that even a short exposure to injurious mechanical ventilation and excessive oxygen exposure may induce lung injury [55]. In the delivery room, CPAP should be used early, and, during bag-mask ventilation, PEEP valves should be used to help establish and stabilize functional residual capacity. It is imperative that ventilation with large tidal volumes is avoided. To reduce the risk of oxygen toxicity, the provision of supplemental oxygen must be guided by pulse oximetry. When preterm infants with HMD fail a trial of CPAP, surfactant should be administered within the first hours of life.

During CMV, lung-protective ventilation can best be achieved by optimizing PEEP and by tidal volume targeting (i.e. 4–6 ml/kg) (fig. 3). Since compliance can change rapidly, particularly after surfactant administration to preterm infants with HMD, the required peak inflation pressures may have to be adjusted frequently. Alternatively, VTV should be used to reduce the risk of volutrau-
ma and hypocapnia [18]. Because the lungs of preterm infants with HMD have short time constants (i.e. the product of compliance and resistance), they can initially be ventilated with short inflation times (0.25–0.4 s). Once compliance improves, inflation times may need to be adjusted to allow inflation flow to return to zero before expiration starts.

During HFOV, an open lung concept must be used by choosing an appropriate level of mean airway pressure guided by improvements in oxygenation (i.e. the ability to reduce FiO₂ to less than 0.25–0.30) [56] and demonstration of adequate lung expansion on conventional chest X-ray at regular intervals. Ventilation, on the other hand, depends on the pressure amplitude and the chosen frequency. With HFOV, an increase in ventilator frequency will decrease CO₂ elimination [57]. Since changes in compliance and resistance affect the corner frequency in opposite directions (i.e. the frequency below which the pressure cost of flow increases sharply), the choice of the optimal frequency during HVOF must be guided by the predominant pathology. In HMD, characterized by low compliance, higher frequencies can be used than, for example, in meconium aspiration syndrome where increased resistance predominates [58, 59].

The concept of permissive hypercapnia may further limit ventilator-induced lung injury regardless of whether CMV or HFOV is used [60]. In selected cases, iNO may improve oxygenation by improving ventilation-perfusion matching or decreasing pulmonary vascular resistance and right-to-left shunting across the ductus arteriosus and/or the foramen ovale. In preterm infants, caffeine should be considered not only for the treatment of apnea of prematurity, but also to facilitate weaning and decrease the duration of mechanical ventilation.

The Future: Any Leaps in Sight?

Defining Appropriate Oxygen Saturation Targets for Preterm Infants

In healthy term infants, with the transition from intrauterine to extrauterine life, arterial oxygen saturation increases substantially from about 65% to more than 95%. The appropriate arterial oxygen saturation target in preterm infants is unknown, and exposure to high concentrations of oxygen is associated with increased risks of ROP and BPD [61]. Several recently published large prospective randomized controlled multicenter trials have addressed this issue [62–65]. Extremely preterm infants with a gestational age of less than 28 weeks were randomized either to a low (i.e. 85–89%) or a high (i.e. 91–95%) target oxygen saturation (SaO₂) group. The Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT) Study Group reported a statistically significantly increased mortality rate among infants in the low SaO₂ group compared to the infants in the high SaO₂ group. On the other hand, rates of moderate-to-severe BPD and severe ROP were significantly lower in the low SaO₂ group [62]. Researchers of the Benefits of Oxygen Saturation Targeting (BOOST II) found a similar trend in preterm infants with a gestational age of less than 28 weeks who were randomized to lower target SaO₂ levels (85–89%) compared to higher target SaO₂ levels (91–95%).

In summary, the appropriate arterial oxygen saturation target in preterm infants is unknown, and the use of lower target SaO₂ levels may decrease the risk of BPD and severe ROP in preterm infants.
mortality rates, which reached statistical significance among infants exposed to a revised oximeter-calibration algorithm [64]. In contrast, the Canadian Oxygen Trial (COT) found comparable rates of death among low and high SaO₂ groups; these results did not change when only infants treated with a revised oximeter-calibration algorithm were analyzed [63]. Finally, both the SUPPORT trial and the COT trial, found no statistically different rates of death or neurodevelopmental impairment at 18–22 months of corrected age [63, 65]. The findings of these trials are summarized in table 2.

Interestingly, causes of death did not differ between the two SaO₂ groups. In addition, the curves of mortality over time between the two SaO₂ target groups appear to diverge only several weeks after birth. The authors of an editorial accompanying the publication of the COT trial have argued that there might be a possible benefit of targeting different SaO₂ ranges at different postnatal ages [66]. Nevertheless, for the time being, it seems prudent to target SaO₂ between 90 and 95% while avoiding extreme oxygenation levels (both hypoxia and hyperoxia) [66, 67].

### Table 2. Main findings of trials evaluating low (85–89%) versus high (91–95%) target oxygen saturations in extremely preterm infants [62–65]

<table>
<thead>
<tr>
<th>Trial [year published]</th>
<th>Population studies</th>
<th>Subgroup n</th>
<th>Randomization SaO₂ target</th>
<th>Outcomes</th>
<th>death</th>
<th>BPD</th>
<th>ROP</th>
<th>NEC</th>
<th>death or NDI</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUPPORT [2010]</td>
<td>24 0/7–27 6/7 weeks</td>
<td>all (1,316)</td>
<td>low</td>
<td>19.9%</td>
<td>37.6%</td>
<td>8.6%</td>
<td>11.9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>16.2%</td>
<td>46.7%</td>
<td>17.9%</td>
<td>10.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p = 0.04</td>
<td>p = 0.002</td>
<td>p &lt; 0.001</td>
<td>n.s.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUPPORT [2012]</td>
<td>24 0/7–27 6/7 weeks</td>
<td>all (1,234)</td>
<td>low</td>
<td>22.1%</td>
<td>37.0%</td>
<td>8.6%</td>
<td>8.8%</td>
<td>30.2%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>18.2%</td>
<td>39.7%</td>
<td>17.4%</td>
<td>8.6%</td>
<td>27.5%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p = 0.046</td>
<td>n.s.</td>
<td>p &lt; 0.001</td>
<td>n.s.</td>
<td>n.s.</td>
<td></td>
</tr>
<tr>
<td>BOOST II [2013]</td>
<td>&lt;28 0/7 weeks</td>
<td>all (2,448)</td>
<td>low</td>
<td>19.2%</td>
<td>35.6%</td>
<td>10.6%</td>
<td>10.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>16.6%</td>
<td>40.0%</td>
<td>13.5%</td>
<td>8.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>n.s.</td>
<td>n.s.</td>
<td>p = 0.045</td>
<td>p = 0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOOST II [2013]</td>
<td>&lt;28 0/7 weeks</td>
<td>revised algorithm (1,187)</td>
<td>low</td>
<td>23.1%</td>
<td>35.6%</td>
<td>9.4%</td>
<td>8.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>15.9%</td>
<td>40.8%</td>
<td>11.4%</td>
<td>6.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p = 0.002</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COT [2013]</td>
<td>23 0/7–27 6/7 weeks</td>
<td>all (1,201)</td>
<td>low</td>
<td>16.6%</td>
<td>31.8%</td>
<td>12.8%</td>
<td>12.3%</td>
<td>51.6%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>15.3%</td>
<td>33.0%</td>
<td>13.1%</td>
<td>9.3%</td>
<td>47.9%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COT [2013]</td>
<td>23 0/7–27 6/7 weeks</td>
<td>revised algorithm (538)</td>
<td>low</td>
<td>16.8%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>52.6%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>high</td>
<td>14.1%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>46.6%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>n.s.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.s.</td>
<td></td>
</tr>
</tbody>
</table>

n.s. = Not significant; n.a. = not available.

### Synchronized Noninvasive Positive Pressure Ventilation

Although experience with early CPAP to stabilize preterm infants and avoid invasive mechanical ventilation has greatly increased, success with this approach is limited [39, 40]. Nasal intermittent positive pressure ventilation could potentially improve noninvasive respiratory support [68, 69]. However, without synchronization, tidal volumes of spontaneously breathing preterm infants are only minimally augmented [70]. Currently used flow, pressure or abdominal motion triggers are unreliable. In recent years, neurally adjusted ventilatory assist, a technique that utilizes the electrical activity of the diaphragm to trigger mechanical breaths, has been shown to improve patient-ventilator interaction and synchrony even in the presence of large air leaks [71]. Whether nasal intermittent positive pressure ventilation with neurally adjusted ventilatory assist will make a difference in important clinical outcomes of preterm infants will have to be evaluated in randomized trials.
Large Potential for Low-Resource Countries

Given the fact that progress made in the last decade has only resulted in minor improvements in mortality and morbidity rates of neonates with respiratory failure, it seems unlikely that further refinements of current technologies will produce giant leaps forward in high-resource countries. It appears that entirely new approaches will be required. In contrast, knowledge and technology transfer of basic respiratory support strategies (e.g. use of oxygen, simple systems to provide CPAP) could have an enormous impact on the prognosis of neonates with respiratory failure in low-resource countries [72, 73].

Disclosure Statement

We declare that we have no conflicts of interest.

References


Berger/Fontana/Stocker